Compare two options for accessing the cash in your home — cash-out refinancing or home equity loans — to pay for renovations, consolidate debt or support education expenses. Includes pros, cons and ...

You should also shop around and compare different lenders. If you're refinancing, specifically, don't hesitate to look beyond your current mortgage lender. You may qualify for different rates and ...

Commissions do not affect our editors' opinions or evaluations. Refinancing your mortgage could be a good choice if you can qualify for better terms, such as a lower interest rate, or to help you ...

Commissions do not affect our editors' opinions or evaluations. If you’re thinking about refinancing your mortgage, it’s a good idea to keep an eye on interest rates as they can fluctuate day ...

U.S. casino group Bally's has offered Star Entertainment a A$250 million ($158 million) recapitalisation package that could give it majority control, as the Australian casino company fights for ...

The funding replaces borrowing that supported the construction of the new 52,888-capacity venue, which is set to open early ...

Specialist capital advisory firm Arc & Co. has recently closed a £27.5m facility to refinance the Bristol Airport Hampton by ...

In addition to the First Lien and Second Lien Term Loans, Alvogen also announced it had successfully amended and extended its existing $240 million ABL revolving credit facility.

Alvogen Pharma US, Inc. ("Alvogen" or the "Company"), a privately owned US-based pharmaceutical company, announced the successful completion of a comprehensive refinancing of its capital structure.

Around 17 tech companies have raised a combined US$6.7 billion from share placements or secondary offerings since February The artificial intelligence (AI) boom that propelled Chinese technology ...

American Hotel Income Properties REIT LP (“AHIP”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB.V), today announced the completion of a non-recourse debt ...

Alvogen Pharma US Inc. has arranged a new private loan led by Centerbridge Partners that will ease near-term refinancing pressure as the generic drugs maker grapples with projected revenue declines.